en
Scientific article
Review
Open access
English

A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma

Published inJournal of experimental & clinical cancer research, vol. 40, no. 1, 189
Publication date2021-06-08
First online date2021-06-08
Abstract

Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related deaths. Recent sequencing and transcriptomics studies have demonstrated the RAS-MAPK pathway's contribution to the development and progression of neuroblastoma. This review compiles up-to-date evidence of this pathway's involvement in neuroblastoma. We discuss the RAS-MAPK pathway's general functioning, the clinical implications of its deregulation in neuroblastoma, and current promising therapeutics targeting proteins involved in signaling.

eng
Keywords
  • ALK
  • ERK1/2
  • Inhibitors
  • MEK1/2
  • Neuroblastoma
  • RAS
  • RAS-MAPK
  • RASopathie
Citation (ISO format)
MLAKAR, Vid et al. A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma. In: Journal of experimental & clinical cancer research, 2021, vol. 40, n° 1, p. 189. doi: 10.1186/s13046-021-01967-x
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
ISSN of the journal1756-9966
134views
67downloads

Technical informations

Creation10/11/2021 12:31:00 PM
First validation10/11/2021 12:31:00 PM
Update time03/16/2023 1:55:44 AM
Status update03/16/2023 1:55:44 AM
Last indexation02/12/2024 12:15:49 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack